Related Experiment Videos
Pharmacist-provided medication therapy management (part 2): Payer perspectives in 2007
Jon C Schommer1, Lourdes G Planas, Kathleen A Johnson
1College of Pharmacy, University of Minnesota, Minneapolis 55455, USA. schom010@umn.edu
Journal of the American Pharmacists Association : Japha
|July 24, 2008
Summary
Payer perspectives on medication therapy management (MTM) reveal varied implementation and monitoring strategies. Future plans include expanded pharmacist-patient interaction to better measure MTM outcomes.
Area of Science:
- Health Services Research
- Pharmacy Practice
- Health Economics
Background:
- Medication Therapy Management (MTM) aims to optimize medication use and improve patient outcomes.
- Understanding payer perspectives is crucial for effective MTM program implementation and scalability.
- Previous research has not fully captured the nuances of MTM service delivery from a payer standpoint.
Purpose of the Study:
- To gather and describe payer viewpoints on MTM implementation strategies.
- To identify methods used for quantifying MTM costs and benefits.
- To explore barriers encountered in offering MTM services.
Main Methods:
- A descriptive, cross-sectional study was conducted in the United States during 2007.
- Data were collected via self-administered online surveys and open-ended telephone interviews.
- 132 payers responded to the survey, with 20 participating in interviews.
Main Results:
- Only 20% of surveyed payers offered MTM services aligned with the consensus definition.
- Significant variation existed in how payers implemented and monitored their MTM programs.
- Payers planned to increase face-to-face pharmacist-patient interactions in 2008.
Conclusions:
- Payers are evolving their MTM strategies, with a focus on enhanced patient interaction.
- Future opportunities exist for longitudinal outcome measurement and strategy adjustments.
- Further validation is required to confirm the long-term impact of these evolving MTM approaches.
Related Concept Videos
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...